Angle Share Discussion Threads

[themizo] 03/5/2024 05:07

Been invested here for over 12 years but first ever post. After the slump that followed FDA approval I stopped following completely. I wouldn’t trust anything Newland says or does and the company’s strategy and execution is utter garbage. The only reason I haven’t cut my losses is because anything that helps cancer patients is worth it. Good luck all!

[bones699] 02/5/2024 18:25

Washingmachine

Newland promises to get your whites whiter than white!

[toffeeman] 02/5/2024 16:20

delivery takes 21 days so they don't hold stock

[countbasie1] 02/5/2024 15:51

5TThanks for posting.

[5oletrader] 02/5/2024 15:47

INTERESTING - European Distributor??
- HiSS Diagnostics was founded in Freiburg in autumn 1989. We have been supplying our customers with high-quality IVD and life science products from selected suppliers for more than 34 years.
- Initially, the focus was on autoimmunity, microbiology, immunology and control materials for quality assurance in medical laboratories. The product range was later expanded to include antibodies for basic research in the areas of immunology, tumor research and neurology and supplemented by purification systems for molecular biology, cell biology and oncology. Over the last 10 years, the focus of our portfolio has shifted to state-of-the-art solutions for oncology and molecular biology (NGS, liquid biopsy).
- Our team consists of highly competent, doctoral scientists with many years of experience and in-depth background knowledge in their respective areas of life sciences. Through regular training and participation in international conferences, we are always up to date with the latest knowledge and are happy to answer any questions you may have.

-
ANGLE:


Parsortix® instrument#ANGLE
- ANGLE's Parsortix® instrument is an in vitro diagnostic device designed to enrich circulating tumor cells (CTCs) with the disposable Parsortix® cell separation cassette from peripheral blood stored in K2EDTA tubes from patients with metastatic disease Breast cancer was collected. The Parsortix® instrument is available as an RUO version, Parsortix® PR1 System, and as an FDA-cleared diagnostic device, Parsortix® PC1 Clinical System.

-

[citys2874] 02/5/2024 13:16

SHOULD BREAK PAST 15.00+ NEXT WEEK EASILY

[kryptonsnake] 02/5/2024 11:15

if most holders believed a 10p placing was imminent the share price would not be around 14p

Insiders would also know and would be forward selling

Look at todays volume

Does it look like a placing is coming?

derampers take a break, you must be exhausted shouting placing and still not a placing in sight


LOLsss

[kirk 6] 02/5/2024 08:53

Buying INDI indus gas at the moment which is incredible cheap

[htrocka2] 02/5/2024 08:48

If you did your job properly at AGL you'd probably still be there....however, the sacking has made you bitter and twisted.

[washingmachine] 02/5/2024 08:00

Rinsed !
Lol

[bones699] 02/5/2024 07:58

This one is heading for the tumble dryer!

[washingmachine] 02/5/2024 07:55

I actually thought the sector had bottomed
But with recent results from the health sector minus the big boys
It’s getting worse
Especially take up on new technologies
Example being APTA POLX and several others Still risk off by the looks

[bones699] 02/5/2024 07:51

Adw198

You need a reality check there will be no £6m of additional revenues this year and the only strategic option is a cash placement at no doubt 20% below current share price probably not far off 10p with Newland promising next year will be different "we are on the cusp of commercialisation"...aka...'more jam tommorrow'...finger waving in the air Newland style!

[washingmachine] 02/5/2024 07:13

Pretty odvious
It’s going to miss
Balancing act with placing
Sit on fence mode

[fhmktg] 02/5/2024 07:10

The results update has been in April for recent years.
No date yet announced for year 2023
Is AN delaying because of anticipated technical or partnership information, or a funding move?
Not long to find out.

[adw198] 01/5/2024 22:03

If they don’t need one prior to Q2 25 then something has gone seriously well, way beyond the company’s own projections. If that’s turns out to be the case the share price would be entitled to be MULTIPLIES of today’s price.

If you’re invested here and not expecting a raise then I think it’s based on nothing more than crossing your fingers and guessing they’ll massively exceed their own forecasts.

[boris cobaka] 01/5/2024 20:26

Some are more desperate than the CO. for a cash raise...

[adw198] 01/5/2024 19:06

The company told us when cash would run out but you seem to think you know better.
But you don’t want to explain any reasoning beyond a 12month old RNs with zero figures mentioned.

So why would I pick up the phone and ask them if there’s an update to the market guidance they’ve provided based on jenko thinking a windfall is coming?!

[jelenko] 01/5/2024 18:59

No idea if I knew I would be an "insider" which I would rather not be. The company wrote the article so I suggest you ask them, go on be brave pick up the phone.

[adw198] 01/5/2024 18:48

@jelenko….its not unreasonable of you think that RNS implies a level of income that might move the current budgeted runway until Q2.

But rather than somewhat defensively slate those of us who instead point to the most recent statements on the funding gap, perhaps you could clarify how much the bioview partnership will deliver, when and whether the company themselves considered this in their calcs in terms of revenue?

[washingmachine] 01/5/2024 18:19

I’m 100 percent with you Arthur

I’ve said before
They will go for approximately 10 million
100 million shares at 10 pence
More than likely already forward sold
Results are over due
Just get it all out of the way Andrew !

[jelenko] 01/5/2024 18:05

Doubt it myself knowing how the company are thinking at the moment. It will be an absolute last resort I can say that.

[arthur_lame_stocks] 01/5/2024 17:59

jelenko

For what it's worth I remain a holder but I think a fundraise is highly likely in the coming months.

[jelenko] 01/5/2024 17:52

I think those people desperate to peddle the fundraise bike in the absence of anything else to hang their hat on would do well to read the following that was published by AGL at the time the BioView HER2 assay project started around a year ago and as we know the assay is now completed, say no more!!


"This changing market dynamic has provided ANGLE and BioView with a major commercial opportunity to develop a quantitative CTC-based HER2 assay, to assess HER2 protein expression and/or gene amplification levels by analysing fluorescence intensities. This would be the only product-based solution on the market for this purpose leveraging both companies' previous FDA product clearances. Unlike current standard of care tests developed for use on FFPE tissue, a CTC HER2 assay could be used for longitudinal monitoring of HER2 status throughout disease progression, thereby ensuring the patient is targeted for the most appropriate treatment at every stage. The development phase is estimated to take around a year to complete with the assay development work generating c. GBP1.2 million of revenues for ANGLE".

Given the significant third-party interest in a new assay for quantitative HER2 analysis based on CTCs, ANGLE and BioView have agreed to allow for the inclusion of third parties in this project and its funding as we move into the commercialisation stage after the initial development work is complete. The parties are continuing to discuss strategic routes to market with potential corporate partners.

[boris cobaka] 01/5/2024 11:58

No City. Volume non existent at the mo. The calm before the longer calm???

Sell in May, go away come back on St Swithin's day....